{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,21]],"date-time":"2026-09-21T08:46:21Z","timestamp":1789980381946,"version":"4.0.1"},"reference-count":45,"publisher":"Springer Science and Business Media LLC","issue":"15","license":[{"start":{"date-parts":[[2016,8,30]],"date-time":"2016-08-30T00:00:00Z","timestamp":1472515200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2016,8,30]],"date-time":"2016-08-30T00:00:00Z","timestamp":1472515200000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Drugs"],"published-print":{"date-parts":[[2016,10]]},"DOI":"10.1007\/s40265-016-0636-6","type":"journal-article","created":{"date-parts":[[2016,8,30]],"date-time":"2016-08-30T02:32:14Z","timestamp":1472524334000},"page":"1467-1476","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":38,"title":["Intravenous Minocycline: A Review in Acinetobacter Infections"],"prefix":"10.1007","volume":"76","author":[{"ORCID":"https:\/\/orcid.org\/0000-0002-0364-8377","authenticated-orcid":false,"given":"Sarah L.","family":"Greig","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Lesley J.","family":"Scott","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2016,8,30]]},"reference":[{"issue":"1","key":"636_CR1","doi-asserted-by":"publisher","first-page":"1","DOI":"10.1086\/595011","volume":"48","author":"HW Boucher","year":"2009","unstructured":"Boucher HW, Talbot GH, Bradley JS, et al. Bad bugs, no drugs: no ESKAPE! An update from the Infectious Diseases Society of America. Clin Infect Dis. 2009;48(1):1\u201312.","journal-title":"Clin Infect Dis"},{"key":"636_CR2","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance threats in the United States. 2013. http:\/\/www.cdc.gov\/drugresistance\/threat-report-2013. Accessed 16 Aug 2016."},{"issue":"12","key":"636_CR3","doi-asserted-by":"publisher","first-page":"1315","DOI":"10.1007\/s40265-014-0267-8","volume":"74","author":"JA Viehman","year":"2014","unstructured":"Viehman JA, Nguyen MH, Doi Y. Treatment options for carbapenem-resistant and extensively drug-resistant Acinetobacter baumannii infections. Drugs. 2014;74(12):1315\u201333.","journal-title":"Drugs."},{"key":"636_CR4","unstructured":"Centers for Disease Control and Prevention. Antibiotic resistance patient safety atlas: data on antibiotic-resistant healthcare-associated infections. 2015. http:\/\/gis.cdc.gov\/grasp\/psa. Accessed 16 Aug 2016."},{"issue":"Suppl 6","key":"636_CR5","doi-asserted-by":"publisher","first-page":"S374","DOI":"10.1093\/cid\/ciu613","volume":"59","author":"DJ Ritchie","year":"2014","unstructured":"Ritchie DJ, Garavaglia-Wilson A. A review of intravenous minocycline for treatment of multidrug-resistant Acinetobacter infections. Clin Infect Dis. 2014;59(Suppl 6):S374\u201380.","journal-title":"Clin Infect Dis"},{"issue":"5","key":"636_CR6","doi-asserted-by":"publisher","first-page":"395","DOI":"10.1016\/j.ijantimicag.2009.06.021","volume":"34","author":"E Bishburg","year":"2009","unstructured":"Bishburg E, Bishburg K. Minocycline\u2014an old drug for a new century: emphasis on methicillin-resistant Staphylococcus aureus (MRSA) and Acinetobacter baumannii. Int J Antimicrob Agents. 2009;34(5):395\u2013401.","journal-title":"Int J Antimicrob Agents"},{"issue":"5","key":"636_CR7","doi-asserted-by":"publisher","first-page":"279","DOI":"10.2146\/ajhp150290","volume":"73","author":"B Colton","year":"2016","unstructured":"Colton B, McConeghy KW, Schreckenberger PC, et al. I.V. minocycline revisited for infections caused by multidrug-resistant organisms. Am J Health Syst Pharm. 2016;73(5):279\u201385.","journal-title":"Am J Health Syst Pharm"},{"key":"636_CR8","unstructured":"The Medicines Company. Minocin\u00ae (minocycline for injection): US prescribing information. 2015. http:\/\/www.fda.gov. Accessed 16 Aug 2016."},{"key":"636_CR9","unstructured":"The Medicines Company. FDA approves new formulation of Minocin\u00ae (minocycline) for injection [media release]. 2015. http:\/\/www.themedicinescompany.com. Published 20 Apr 2015."},{"issue":"1","key":"636_CR10","doi-asserted-by":"publisher","first-page":"21","DOI":"10.1002\/jhm.2477","volume":"11","author":"MD Zilberberg","year":"2016","unstructured":"Zilberberg MD, Kollef MH, Shorr AF. Secular trends in Acinetobacter baumannii resistance in respiratory and blood stream specimens in the United States, 2003 to 2012: a survey study. J Hosp Med. 2016;11(1):21\u20136.","journal-title":"J Hosp Med."},{"key":"636_CR11","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1016\/j.ijid.2016.06.016","volume":"49","author":"M T\u00e4rnberg","year":"2016","unstructured":"T\u00e4rnberg M, Nilsson LE, Dowzicky MJ. Antimicrobial activity against a global collection of skin and skin structure pathogens: results from the tigecycline evaluation and surveillance trial (T.E.S.T.), 2010-2014. Int J Infect Dis. 2016;49:141\u20138.","journal-title":"Int J Infect Dis."},{"issue":"1","key":"636_CR12","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/s12941-015-0085-1","volume":"14","author":"DJ Hoban","year":"2015","unstructured":"Hoban DJ, Reinert RR, Bouchillon SK, et al. Global in vitro activity of tigecycline and comparator agents: tigecycline evaluation and surveillance trial 2004\u20132013. Ann Clin Microbiol Antimicrob. 2015;14(1):27.","journal-title":"Ann Clin Microbiol Antimicrob."},{"key":"636_CR13","first-page":"A5830","volume":"183","author":"SK Bouchillon","year":"2011","unstructured":"Bouchillon SK, Hackel M, Hoban D, et al. Evaluating multi-drug resistant Acinetobacter baumannii in critical care units [abstract no. K9 plus poster]. Am J Respir Crit Care Med. 2011;183:A5830.","journal-title":"Am J Respir Crit Care Med"},{"issue":"4","key":"636_CR14","doi-asserted-by":"publisher","first-page":"1286","DOI":"10.1128\/JCM.03184-14","volume":"53","author":"SC Kehl","year":"2015","unstructured":"Kehl SC, Dowzicky MJ. Global assessment of antimicrobial susceptibility among Gram-negative organisms collected from pediatric patients between 2004 and 2012: results from the tigecycline evaluation and surveillance trial. J Clin Microbiol. 2015;53(4):1286\u201393.","journal-title":"J Clin Microbiol"},{"key":"636_CR15","doi-asserted-by":"publisher","first-page":"24","DOI":"10.1186\/1476-0711-12-24","volume":"12","author":"GA Denys","year":"2013","unstructured":"Denys GA, Callister SM, Dowzicky MJ. Antimicrobial susceptibility among Gram-negative isolates collected in the USA between 2005 and 2011 as part of the tigecycline evaluation and surveillance trial (T.E.S.T.). Ann Clin Microbiol Antimicrob. 2013;12:24.","journal-title":"Ann Clin Microbiol Antimicrob."},{"issue":"Suppl 6","key":"636_CR16","doi-asserted-by":"publisher","first-page":"S367","DOI":"10.1093\/cid\/ciu706","volume":"59","author":"M Castanheira","year":"2014","unstructured":"Castanheira M, Mendes RE, Jones RN. Update on Acinetobacter species: mechanisms of antimicrobial resistance and contemporary in vitro activity of minocycline and other treatment options. Clin Infect Dis. 2014;59(Suppl 6):S367\u201373.","journal-title":"Clin Infect Dis"},{"issue":"3","key":"636_CR17","doi-asserted-by":"publisher","first-page":"352","DOI":"10.1016\/j.diagmicrobio.2016.03.019","volume":"85","author":"RK Flamm","year":"2016","unstructured":"Flamm RK, Castanheira M, Streit JM, et al. Minocycline activity tested against Acinetobacter baumannii complex, Stenotrophomonas maltophilia and Burkholderia cepacia species complex isolates from a global surveillance program (2013). Diagn Microbiol Infect Dis. 2016;85(3):352\u20135.","journal-title":"Diagn Microbiol Infect Dis"},{"key":"636_CR18","unstructured":"Pfizer. Tygacil\u00ae (tigecycline) for injection, for intravenous use: US prescribing information. 2016. http:\/\/www.fda.gov. Accessed 16 Aug 2016."},{"key":"636_CR19","unstructured":"Sahm D, Biedenbach D, Leister-Tebbe H. Antimicrobial susceptibility profiles for multi-drug resistant (MDR) Acinetobacter spp: a global perspective (TEST 2011\u20132014) [abstract no. C-1016 plus poster]. In: ICAAC. 2015."},{"key":"636_CR20","unstructured":"Bowker KE, Noel AR, Tomaselli SG, et al. Pharmacodynamics of minocycline against Acinetobacter baumannii studied in a pharmacokinetic model of infection [abstract no. A040]. In: ICAAC. 2014."},{"issue":"5","key":"636_CR21","doi-asserted-by":"publisher","first-page":"2720","DOI":"10.1128\/AAC.04110-14","volume":"59","author":"DR Bowers","year":"2015","unstructured":"Bowers DR, Cao H, Zhou J, et al. Assessment of minocycline and polymyxin B combination against Acinetobacter baumannii. Antimicrob Agents Chemother. 2015;59(5):2720\u20135.","journal-title":"Antimicrob Agents Chemother"},{"key":"636_CR22","first-page":"507","volume":"6","author":"S He","year":"2015","unstructured":"He S, He H, Chen Y, et al. In vitro and in vivo analysis of antimicrobial agents alone and in combination against multi-drug resistant Acinetobacter baumannii. Front Microbiol. 2015;6:507.","journal-title":"Front Microbiol."},{"issue":"10","key":"636_CR23","doi-asserted-by":"publisher","first-page":"1196","DOI":"10.1099\/jmm.0.000147","volume":"64","author":"CH Rodriguez","year":"2015","unstructured":"Rodriguez CH, Nastro M, Vay C, et al. In vitro activity of minocycline alone or in combination in multidrug-resistant Acinetobacter baumannii isolates. J Med Microbiol. 2015;64(10):1196\u2013200.","journal-title":"J Med Microbiol"},{"key":"636_CR24","doi-asserted-by":"publisher","first-page":"109","DOI":"10.1186\/1471-2334-11-109","volume":"11","author":"W Liang","year":"2011","unstructured":"Liang W, Liu XF, Huang J, et al. Activities of colistin- and minocycline-based combinations against extensive drug resistant Acinetobacter baumannii isolates from intensive care unit patients. BMC Infect Dis. 2011;11:109.","journal-title":"BMC Infect Dis"},{"issue":"7","key":"636_CR25","doi-asserted-by":"publisher","first-page":"4047","DOI":"10.1128\/AAC.02994-15","volume":"60","author":"YS Yang","year":"2016","unstructured":"Yang YS, Lee Y, Tseng KC, et al. In vivo and in vitro efficacy of minocycline-based combination therapy for minocycline-resistant Acinetobacter baumannii. Antimicrob Agents Chemother. 2016;60(7):4047\u201354.","journal-title":"Antimicrob Agents Chemother"},{"key":"636_CR26","unstructured":"Tarazi Z, Sabet M, Dudley MN, et al. Pharmacodynamics of minocycline against Acinetobacter baumannii in a rat pneumonia model [abstract]. In: ICAAC. 2015."},{"key":"636_CR27","unstructured":"Zhou J, Ledesma KR, Tam VH. In vivo efficacy of minocycline for infections caused by Acinetobacter baumannii [abstract]. In: ICAAC. 2015."},{"issue":"1","key":"636_CR28","doi-asserted-by":"publisher","first-page":"651","DOI":"10.1128\/AAC.01751-12","volume":"57","author":"E Vilacoba","year":"2013","unstructured":"Vilacoba E, Almuzara M, Gulone L, et al. Emergence and spread of plasmid-borne tet(B):ISCR2 in minocycline-resistant Acinetobacter baumannii isolates. Antimicrob Agents Chemother. 2013;57(1):651\u20134.","journal-title":"Antimicrob Agents Chemother"},{"issue":"7","key":"636_CR29","doi-asserted-by":"publisher","first-page":"1574","DOI":"10.1017\/S0950268815002897","volume":"144","author":"E Vilacoba","year":"2016","unstructured":"Vilacoba E, Almuzara M, Gulone L, et al. Widespread dispersion of the resistance element tet(B):ISCR2 in XDR Acinetobacter baumannii isolates. Epidemiol Infect. 2016;144(7):1574\u20138.","journal-title":"Epidemiol Infect"},{"issue":"11","key":"636_CR30","doi-asserted-by":"publisher","first-page":"5247","DOI":"10.1128\/AAC.00730-13","volume":"57","author":"C Rumbo","year":"2013","unstructured":"Rumbo C, Gato E, L\u03ccpez M, et al. Contribution of efflux pumps, porins, and \u03b2-lactamases to multidrug resistance in clinical isolates of Acinetobacter baumannii. Antimicrob Agents Chemother. 2013;57(11):5247\u201357.","journal-title":"Antimicrob Agents Chemother"},{"key":"636_CR31","unstructured":"Lomovskaya O, Sun D, Rubio-Aparicio D, et al. Accumulation of several chromosomal mutations have limited impact on the sensitivity of Acinetobacter baumannii (ACB) to minocycline (MINO) [abstract no. C-1009 plus poster]. In: ICAAC. 2015."},{"key":"636_CR32","unstructured":"Lomovskaya O, Sun D, King P, et al. Tigecycline (TIG) but not minocycline (MINO) readily selects for clinically relevant efflux-mediated resistance (R) in Acinetobacter spp. (ACB) [abstract no. C1-1087 plus poster]. In: ICAAC. 2013."},{"issue":"3","key":"636_CR33","doi-asserted-by":"publisher","first-page":"403","DOI":"10.1111\/j.1574-695X.2011.00926.x","volume":"64","author":"AC Jacobs","year":"2012","unstructured":"Jacobs AC, Sayood K, Olmsted SB, et al. Characterization of the Acinetobacter baumannii growth phase-dependent and serum responsive transcriptomes. FEMS Immunol Med Microbiol. 2012;64(3):403\u201312.","journal-title":"FEMS Immunol Med Microbiol"},{"issue":"11","key":"636_CR34","doi-asserted-by":"publisher","first-page":"6360","DOI":"10.1128\/AAC.03535-14","volume":"58","author":"C Blanchard","year":"2014","unstructured":"Blanchard C, Barnett P, Perlmutter J, et al. Identification of Acinetobacter baumannii serum-associated antibiotic efflux pump inhibitors. Antimicrob Agents Chemother. 2014;58(11):6360\u201370.","journal-title":"Antimicrob Agents Chemother"},{"issue":"Suppl 6","key":"636_CR35","doi-asserted-by":"publisher","first-page":"S381","DOI":"10.1093\/cid\/ciu593","volume":"59","author":"DA Goff","year":"2014","unstructured":"Goff DA, Bauer KA, Mangino JE. Bad bugs need old drugs: a stewardship program\u2019s evaluation of minocycline for multidrug-resistant Acinetobacter baumannii infections. Clin Infect Dis. 2014;59(Suppl 6):S381\u20137.","journal-title":"Clin Infect Dis"},{"issue":"1","key":"636_CR36","doi-asserted-by":"publisher","first-page":"26","DOI":"10.1097\/IPC.0b013e31828bbb82","volume":"22","author":"E Bishburg","year":"2014","unstructured":"Bishburg E, Shah M, Chan T. Use of intravenous minocycline for the treatment of methicillin-resistant Staphylococcus aureus (MRSA) and resistant Gram-negative organisms: experience in a tertiary care hospital. Infect Dis Clin Pract. 2014;22(1):26\u201331.","journal-title":"Infect Dis Clin Pract."},{"issue":"11","key":"636_CR37","doi-asserted-by":"publisher","first-page":"2072","DOI":"10.1007\/s00134-003-1811-2","volume":"29","author":"GC Wood","year":"2003","unstructured":"Wood GC, Hanes SD, Boucher BA, et al. Tetracyclines for treating multidrug-resistant Acinetobacter baumannii ventilator-associated pneumonia. Intensive Care Med. 2003;29(11):2072\u20136.","journal-title":"Intensive Care Med"},{"issue":"Suppl 6","key":"636_CR38","doi-asserted-by":"publisher","first-page":"S388","DOI":"10.1093\/cid\/ciu594","volume":"59","author":"JM Pogue","year":"2014","unstructured":"Pogue JM, Neelakanta A, Mynatt RP, et al. Carbapenem-resistance in Gram-negative bacilli and intravenous minocycline: an antimicrobial stewardship approach at the Detroit Medical Center. Clin Infect Dis. 2014;59(Suppl 6):S388\u201393.","journal-title":"Clin Infect Dis"},{"issue":"6","key":"636_CR39","doi-asserted-by":"publisher","first-page":"343","DOI":"10.1177\/0885066610377975","volume":"25","author":"JD Chan","year":"2010","unstructured":"Chan JD, Graves JA, Dellit TH. Antimicrobial treatment and clinical outcomes of carbapenem-resistant Acinetobacter baumannii ventilator-associated pneumonia. J Intensive Care Med. 2010;25(6):343\u20138.","journal-title":"J Intensive Care Med."},{"issue":"3","key":"636_CR40","doi-asserted-by":"publisher","first-page":"184","DOI":"10.1097\/IPC.0b013e318245d50a","volume":"20","author":"CA Jankowski","year":"2012","unstructured":"Jankowski CA, Balada-Llasat JM, Raczkowski M, et al. A stewardship approach to combating multidrug-resistant acinetobacter baumannii infections with minocycline. Infect Dis Clin Pract. 2012;20(3):184\u20137.","journal-title":"Infect Dis Clin Pract."},{"issue":"5","key":"636_CR41","doi-asserted-by":"publisher","first-page":"455","DOI":"10.1016\/j.ijantimicag.2014.12.031","volume":"45","author":"ME Falagas","year":"2015","unstructured":"Falagas ME, Vardakas KZ, Kapaskelis A, et al. Tetracyclines for multidrug-resistant Acinetobacter baumannii infections. Int J Antimicrob Agents. 2015;45(5):455\u201360.","journal-title":"Int J Antimicrob Agents"},{"issue":"9","key":"636_CR42","doi-asserted-by":"publisher","first-page":"1329","DOI":"10.1016\/j.clinthera.2005.09.005","volume":"27","author":"K Smith","year":"2005","unstructured":"Smith K, Leyden JJ. Safety of doxycycline and minocycline: a systematic review. Clin Ther. 2005;27(9):1329\u201342.","journal-title":"Clin Ther"},{"key":"636_CR43","doi-asserted-by":"publisher","DOI":"10.1093\/cid\/ciw353","author":"AC Kalil","year":"2016","unstructured":"Kalil AC, Metersky ML, Klompas M, et al. Management of adults with hospital-acquired and ventilator-associated pneumonia: 2016 clinical practice guidelines by the Infectious Diseases Society of America and the American Thoracic Society. Clin Infect Dis. 2016. doi:10.1093\/cid\/ciw353.","journal-title":"Clin Infect Dis"},{"issue":"2","key":"636_CR44","doi-asserted-by":"publisher","first-page":"580","DOI":"10.1097\/CCM.0b013e31827e83af","volume":"41","author":"RP Dellinger","year":"2013","unstructured":"Dellinger RP, Levy MM, Rhodes A, et al. Surviving sepsis campaign: international guidelines for management of severe sepsis and septic shock: 2012. Crit Care Med. 2013;41(2):580\u2013637.","journal-title":"Crit Care Med"},{"issue":"3","key":"636_CR45","doi-asserted-by":"publisher","first-page":"299","DOI":"10.2217\/fmb.13.167","volume":"9","author":"IK Neonakis","year":"2014","unstructured":"Neonakis IK, Spandidos DA, Petinaki E. Is minocycline a solution for multidrug-resistant Acinetobacter baumannii? Future Microbiol. 2014;9(3):299\u2013305.","journal-title":"Future Microbiol."}],"container-title":["Drugs"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0636-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s40265-016-0636-6\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s40265-016-0636-6.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,4,15]],"date-time":"2025-04-15T11:04:48Z","timestamp":1744715088000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s40265-016-0636-6"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2016,8,30]]},"references-count":45,"journal-issue":{"issue":"15","published-print":{"date-parts":[[2016,10]]}},"alternative-id":["636"],"URL":"https:\/\/doi.org\/10.1007\/s40265-016-0636-6","relation":{},"ISSN":["0012-6667","1179-1950"],"issn-type":[{"value":"0012-6667","type":"print"},{"value":"1179-1950","type":"electronic"}],"subject":[],"published":{"date-parts":[[2016,8,30]]},"assertion":[{"value":"30 August 2016","order":1,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Compliance with Ethical Standards"}},{"value":"The preparation of this review was not supported by any external funding.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Funding"}},{"value":"Sarah Greig and Lesley Scott are salaried employees of Adis\/Springer, are responsible for the article content and declare no relevant conflicts of interest.","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflicts of interest"}}]}}